



(51) International Patent Classification:

G16H 10/20 (2018.01) G06Q 10/087 (2023.01)
B65B 65/00 (2006.01) G16H 20/10 (2018.01)
G06Q 10/083 (2024.01)

(21) International Application Number:

PCT/US2023/075025

(22) International Filing Date:

25 September 2023 (25.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/411,333 29 September 2022 (29.09.2022) US

(71) Applicant: **R.P. SCHERER TECHNOLOGIES, LLC**
[US/US]; 112 North Curry Street, Carson City, Nevada
89703 (US).

(72) Inventors: **MCCORRY, Mark**; 135 Dale Avenue,
Cambuslang, South Lanarkshire, Glasgow G72 7EY
(GB). **IYADURAI, Sakunthaladevi**; 7 Flanigan Street,
Lawrenceville, New Jersey 08648 (US). **FLAHERTY,
Stephen**; 76 Treen Road, Tyldesley, Greater Manchester
M29 7HA (GB). **FREEMAN, Andrew**; 18 Vicarage Cres-
cent, Coppull, Chorley Lancashire PR7 4QG (GB).

(74) Agent: **VOGLER, Nathan** et al.; Morrison & Foerster LLP,
2100 L ST, NW, Suite 900, Washington, District of Colum-
bia 20037 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: SYSTEMS AND METHODS FOR AGGREGATING SUPPLY ORDERS FOR PHARMACEUTICAL TRIALS




FIG. 1

(57) Abstract: Embodiments of the present disclosure include systems and methods for confidentially producing shipment orders for clinical trials. The method includes receiving a plurality of supply orders associated with one or more clinical trials and determining a clinical trial study, a site location, and a treatment type. A first plurality of supply orders are assigned to a packaging site based on the site location. The method further includes, associating a first sub-group of the first plurality of supply orders with a first assembly procedure, associating a second sub-group of the plurality of supply orders with a second assembly procedure, and assigning, randomly, the plurality of kit identifiers to the first sub-group and the second subgroup, thereby creating a plurality of blinded kits. The method further includes confidentially producing shipment orders for the first plurality of clinical trials based on the plurality of blinded kits.

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*